Better Steps Taken In The Safety Of Tuberculosis Patients
There are many diseases in the human body and many medicines are taken to get rid of these diseases, but sometimes the effect of these medicines is stopped, because taking on medicine for a long time,builds up an immunity inside the body,who is named MDR(Multi Drag resistant).In India, the same is happening in the treatment of tuberculosis.Generic drugs used in tuberculosis treatment stop working by which the number of patients is continuously increasing in India.
But a positive step was taken by the Government of India in this. American pharmaceutical company Johnson & Johnson manufactures a drug related to tuberculosis disease named bedaquiline. He had patented this medicine, due to which its price was available in India for $ 400 i.e. approximately ₹ 21000 per month.When ordinary medicines of Sab tuberculosis stop working than Johnson & Johnson’s is used. There are about 55000 tuberculosis patients in India who need this medicine but due to high cost only 11000 patients get this bedaquiline medicine.
Johnson & Johnson’s bedaquiline drug patent to expire in India in July 2023. That’s why Johnson and Johnson company applied for a second patent for the drug in indian patent office,but Indian patent office didn’t give permission for the patent.
That is, now this drug will come in the market as a generic drug in India in the coming time and companies like Lupik and Maclerds will supply it in India.
Because it is the goal of the Government of India that by 2025 India has to be a tuberculosis free country and if medicines like bedaquiline are accessible to all classes then soon India will achieve its goal.
Although this will make big pharmaceutical companies angry and Research thinking will be less in these companies.But India wants to be known as a seller of cheap generic drugs all over the world and with the help of Etawah India will be known as tuberculosis free country.